News Details

( 10/01/2018 12:09)
Aurobindo Pharma - Investor Grievance Report For The Quarter Ended 31.12.2017

Pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we furnish hereunder the Investor Grievance Report for the Quarter ended 31.12.2017.

Scores Registration No. --- A00384

No. of Investor complaints pending at the beginning of the quarter --- Nil

No. of Investor complaints received during the quarter --- 5

No. of Investor complaints disposed off during the quarter --- 5

No. of Investor complaints pending un-resolved at the end of the quarter --- Nil

ATTENTION INVESTORS 1 : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case | 2 : "Prevent Unauthorized Transactions in your demat / trading account --> Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors. | 3 : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

SEBI Regn. NSE: INB231280430 I F&O: INF231280430 I BSE: INB011280436 I NSE CD: INE231280430 I MCX-SX: INE261280430

Copyright © 2017 Rikhav Securities Ltd. All rights reserved

Designed , Developed & Content Powered by DION